Response to Faricimab for Anti-Vascular Endothelial Growth Factor Resistant Eyes with Neovascular Age-related Macular Degeneration

Abstract We evaluated the response to faricimab in a retrospective series of neovascular age-related macular degeneration (nAMD) eyes with persistent edema or subretinal fluid on other existing anti-VEGF drugs. Inclusion criteria were at least 3 faricimab injections with 6 months follow-up. We also determined the subtypes of nAMD such as polypoidal choroidal vasculopathy (PCV) or non-PCV. Intervals between injections were extended as long as the macula remained dry. Thirteen eyes of thirteen patients were included. Mean age was 77.1 ± 9.3 years. Six were males and seven were females. All eyes had type 1 choroidal neovascularization (CNV) (CNV below the retinal pigment epithelium (RPE), and ten had PCV and three had occult CNV (non-PCV). Faricimab resolved the macula edema in 69.2% of anti-VEGF resistant eyes after three injections. Neither central retinal thickness nor visual acuity significantly changed 6 months after faricimab injections were started. The mean interval of injections before and after faricimab therapy did not change and was 5.3 ± 1.5 and 5.4 ± 0.8 weeks. Central retinal thickness, visual acuity, and the interval of injections were not significantly different between PCV and non-PCV subtypes of exudative AMD.